New Data Highlights Clinical Utility and Performance of Castle Biosciences’ Dermatologic Test Portfolio at the 2023 Fall Clinical Dermatology Conference®
18 Outubro 2023 - 5:30PM
Business Wire
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving
health through innovative tests that guide patient care, today
announced that it will share new data across its dermatologic
portfolio of gene expression profile (GEP) tests at the 2023 Fall
Clinical Dermatology Conference® (FC23), taking place Oct. 19-22,
2023, in Las Vegas.
“The breadth of data we are sharing at Fall Clinical reinforces
our commitment to improving the care of patients with skin cancers
and inflammatory skin conditions through innovative tests that can
guide more informed disease management decisions,” said Derek
Maetzold, president and chief executive officer of Castle
Biosciences.
Details regarding Castle’s posters at FC23 are included below.
Posters will be available for viewing for the duration of the
conference.
- Using 31-gene expression profile testing to help guide
adjuvant therapy and sentinel lymph node biopsy discussions with
patients: A case series Lead Author: Peter Prieto, M.D., MPH,
University of Rochester Medical Center
- Association of a 40-gene expression profile with risk of
metastatic disease progression of cutaneous squamous cell carcinoma
(cSCC) and benefit of adjuvant radiation therapy (ART) Lead
Author: Sarah Arron, M.D., Ph.D., Peninsula Dermatology
- Incorporating the 40-gene expression profile (40-GEP) test
within each clinicopathologic staging system improves metastatic
risk-stratification in patients diagnosed with cutaneous squamous
cell carcinoma (cSCC) and one or more high risk factors Lead
Author: Ashley Wysong, M.D., M.S., University of Nebraska Medical
Center
- Use of the 40-gene expression profile (40-GEP) test in
Medicare-eligible patients diagnosed with cutaneous squamous cell
carcinoma (cSCC) to guide adjuvant radiation therapy (ART)
decisions leads to a significant reduction in healthcare costs
Lead Authors: Anesh Prasai, Ph.D., Castle Biosciences, and Matthew
S. Goldberg, M.D., Castle Biosciences and Icahn School of Medicine
at Mount Sinai
- Performance of the 23-gene expression profile (23-GEP) test
by histopathological evaluation in an independent, multi-center
performance cohort of cutaneous melanocytic neoplasms Lead
Author: Matthew S. Goldberg, M.D., Castle Biosciences and Icahn
School of Medicine at Mount Sinai
- Gene expression differences identified in skin samples of
early-stage mycosis fungoides, atopic dermatitis, and psoriasis
Lead Author: Aaron S. Farberg, M.D., Baylor Scott & White
Health System and Bare Dermatology Specific details regarding this
poster will be shared following the FC23 conference.
About DecisionDx®-Melanoma DecisionDx-Melanoma is a gene
expression profile risk stratification test. It is designed to
inform two clinical questions in the management of cutaneous
melanoma: a patient’s individual risk of sentinel lymph node (SLN)
positivity and a patient's personal risk of melanoma recurrence
and/or metastasis. By integrating tumor biology with clinical and
pathologic factors using a validated proprietary algorithm,
DecisionDx-Melanoma is designed to provide a comprehensive and
clinically actionable result to guide risk-aligned patient care.
DecisionDx-Melanoma has been shown to be associated with improved
patient survival and has been studied in more than 10,000 patient
samples. DecisionDx-Melanoma’s clinical value is supported by more
than 40 peer-reviewed and published studies, providing confidence
in disease management plans that incorporate the test’s results.
Through June 30, 2023, DecisionDx-Melanoma has been ordered more
than 137,200 times for patients diagnosed with cutaneous
melanoma.
About DecisionDx®-SCC DecisionDx-SCC is a 40-gene
expression profile test that uses an individual patient’s tumor
biology to predict individual risk of cutaneous squamous cell
carcinoma metastasis for patients with one or more risk factors.
The test result, in which patients are stratified into a Class 1
(low), Class 2A (moderate) or Class 2B (high) risk category,
predicts individual metastatic risk to inform risk-appropriate
management. Peer-reviewed publications have demonstrated that
DecisionDx-SCC is an independent predictor of metastatic risk and
that integrating DecisionDx-SCC with current prognostic methods can
add positive predictive value to clinician decisions regarding
staging and management.
About MyPath® Melanoma MyPath Melanoma is Castle’s gene
expression profile test designed to provide an accurate, objective
result to aid dermatopathologists and dermatologists in
characterizing difficult-to-diagnose melanocytic lesions. Of the
approximately two million suspicious pigmented lesions biopsied
annually in the U.S., Castle estimates that approximately 300,000
of those cannot be confidently classified as either benign or
malignant through traditional histopathology methods. For these
cases, the treatment plan can also be uncertain. Obtaining
accurate, objective ancillary testing can mean the difference
between a path of overtreatment or the risk of undertreatment.
Interpreted in the context of other clinical, laboratory and
histopathologic information, MyPath Melanoma is designed to reduce
uncertainty and provide confidence for dermatopathologists and help
dermatologists deliver more informed patient management plans.
More information about Castle’s tests can be found at
www.CastleTestInfo.com.
About Castle’s Inflammatory Skin Disease Pipeline Test
Inflammatory skin disease accounts for a significant number of
patient visits to both primary care and dermatology clinics across
the United States every year. Psoriasis and atopic dermatitis are
among the most common inflammatory skin conditions, and patient
quality of life is severely impacted by these chronic diseases.
Fortunately, systemic medications developed over the past 15 years
have demonstrated a significant improvement in patients’ lives. In
the United States alone, there are about 18 million patients
diagnosed with psoriasis and atopic dermatitis, and approximately
450,000 patients annually are eligible for these systemic
therapies. While there are now many effective treatments options
available for those with moderate-to-severe inflammatory skin
diseases, current clinical practice relies on a trial-and-error
approach for therapy selection. To answer this unmet clinical need,
Castle Biosciences is developing a gene expression profile test to
help guide systemic therapy selection for patients with
moderate-to-severe psoriasis, atopic dermatitis and other related
diseases.
About Castle Biosciences Castle Biosciences (Nasdaq:
CSTL) is a leading diagnostics company improving health through
innovative tests that guide patient care. The Company aims to
transform disease management by keeping people first: patients,
clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers,
uveal melanoma, Barrett’s esophagus and mental health conditions.
Additionally, the Company has active research and development
programs for tests in other diseases with high clinical need,
including its test in development to predict systemic therapy
response in patients with moderate-to-severe psoriasis, atopic
dermatitis and related conditions. To learn more, please visit
www.CastleBiosciences.com and connect with us on LinkedIn,
Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, MyPath
Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq,
TissueCypher and IDgenetix are trademarks of Castle Biosciences,
Inc.
Forward-Looking Statements This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended, which are subject to
the “safe harbor” created by those sections. These forward-looking
statements include, but are not limited to, statements concerning:
our ability to improve the care of patients with skin cancers and
inflammatory skin conditions through innovative tests that can
guide more informed disease management decisions; the potential of
DecisionDx-Melanoma test results to inform two clinical questions
in the management of cutaneous melanoma: a patient’s individual
risk of SLN positivity and a patient’s personal risk of melanoma
recurrence and/or metastasis; the potential of DecisionDx-SCC test
results to predict individual risk of cutaneous squamous cell
carcinoma metastasis for patients with one or more risk factors;
the potential of MyPath Melanoma to provide an accurate, objective
result to aid dermatopathologists and dermatologists in
characterizing difficult-to-diagnose melanocytic lesions; and the
potential of our inflammatory skin disease pipeline test to help
guide systemic therapy selection for patients with
moderate-to-severe psoriasis, atopic dermatitis and other related
diseases. The words “can,” “may” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. We may
not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements, and you should not
place undue reliance on our forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements that we make. These forward-looking statements involve
risks and uncertainties that could cause our actual results to
differ materially from those in the forward-looking statements,
including, without limitation: subsequent study or trial results
and findings may contradict earlier study or trial results and
findings, including with respect to the discussion of
DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma and Castle’s
inflammatory skin disease pipeline test in this press release;
actual application of our tests may not provide the aforementioned
benefits to patients; and the risks set forth under the heading
“Risk Factors” in our Annual Report on Form 10-K for the year ended
December 31, 2022, our Quarterly Report on Form 10-Q for the three
months ended June 30, 2023, and in our other filings with the SEC.
The forward-looking statements are applicable only as of the date
on which they are made, and we do not assume any obligation to
update any forward-looking statements, except as may be required by
law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231018483828/en/
Investor Contact: Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact: Allison Marshall
amarshall@castlebiosciences.com
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Castle Biosciences (NASDAQ:CSTL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024